Sigma Labs, Inc. (OTCMKTS:SGLB) Fails to Take Off

After revving its engines and showing signs of reversal last Thursday, the share price of Sigma Labs, Inc. (OTCMKTS:SGLB) took two consecutive steps down over the next two sessions, reaching a close of $0.21 yesterday. Share volume was below the average, at 5.4 million shares changing hands.

Traders probably expected Sigma to repeat the pattern where it hit a new 52-week high after a retrace and the 9% green close hinted at that but it didn’t happen. In the next two trading sessions SGLB wiped out that climb and returned flat to where it was before the reversal.

It’s been several weeks since the company posted its latest press announcement and the fluctuations are not fueled by external factors. Online discussion boards have gradually shifted from a flamboyant optimism to a more level-headed outlook. The situation around the company has not changed drastically but traders seem to be more cautions, with share volume for SGLB gradually dropping.

The blog published by what appears to be an avid SGLB supporter is still pushing out hugely optimistic articles, hinting that other 3D printing companies have little to no quality assurance in place and will eventually need to turn to SGLB and its PrintRite. With commercialization still scheduled for fiscal 2014 and keeping in mind that deadline was once delayed, it’s probably a good idea to tread carefully. While SGLB has a chance to make it, there’s no assurance of that at the moment.

Other OTC companies were far less fortunate in yesterday’s session. Nutranomics, Inc., f/k/a Buka Ventures Inc. (OTCBB:NNRX) tanked 54% on over 13 million shares traded. The previous time the company shifted so many shares in a day was the late September pump targeting it came crashing down. Brainstorm Cell Therapeutics, Inc. (OTCBB:BCLI) dropped nearly 15% on heavy volume after spending the last three months in a state of slow decay.